Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 6,100 Shares of Stock

Myriad Genetics, Inc. (NASDAQ:MYGN) Director S. Louise Phanstiel acquired 6,100 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was purchased at an average price of $4.74 per share, for a total transaction of $28,914.00. Following the acquisition, the director directly owned 183,544 shares of the company’s stock, valued at $869,998.56. The trade was a 3.44% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

S. Louise Phanstiel also recently made the following trade(s):

• On Friday, February 27th, S. Louise Phanstiel acquired 48,000 shares of Myriad Genetics stock. The stock was acquired at an average cost of $4.66 per share, with a total value of $223,680.00.
• On Thursday, February 26th, S. Louise Phanstiel acquired 50,407 shares of Myriad Genetics stock. The stock was acquired at an average price of $4.80 per share, with a total value of $241,953.60.

Myriad Genetics Trading Down 5.1%

Myriad Genetics stock opened at $4.61 on Friday. Myriad Genetics, Inc. has a one year low of $3.76 and a one year high of $11.44. The company’s fifty day moving average price is $5.61 and its two-hundred day moving average price is $6.59. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.12. The company has a market capitalization of $431.08 million, a price-to-earnings ratio of -1.17 and a beta of 1.90.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.06. Myriad Genetics had a negative return on equity of 6.35% and a negative net margin of 44.38%.The company had revenue of $209.80 million during the quarter, compared to the consensus estimate of $207.57 million. During the same quarter in the prior year, the company posted $0.03 EPS. The firm’s revenue was down .4% on a year-over-year basis. On average, analysts forecast that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Myriad Genetics

Several institutional investors and hedge funds have recently bought and sold shares of MYGN. EverSource Wealth Advisors LLC lifted its holdings in shares of Myriad Genetics by 2,333.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock worth $25,000 after acquiring an additional 4,480 shares during the period. Quarry LP raised its position in Myriad Genetics by 155.6% in the fourth quarter. Quarry LP now owns 4,365 shares of the company’s stock worth $27,000 after purchasing an additional 2,657 shares in the last quarter. Hantz Financial Services Inc. lifted its stake in Myriad Genetics by 1,088.7% during the third quarter. Hantz Financial Services Inc. now owns 4,089 shares of the company’s stock worth $30,000 after purchasing an additional 3,745 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Myriad Genetics by 407.3% during the second quarter. Nisa Investment Advisors LLC now owns 5,773 shares of the company’s stock valued at $31,000 after purchasing an additional 4,635 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Myriad Genetics by 129.6% in the 4th quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock valued at $31,000 after purchasing an additional 2,818 shares during the period. Institutional investors own 99.02% of the company’s stock.

Trending Headlines about Myriad Genetics

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Director S. Louise Phanstiel completed multiple open-market buys totaling ~104,507 shares across Feb. 25–27 (average prices ~$4.74–$4.80), increasing her stake ~20–27% in disclosed filings — a strong insider-confidence signal that can attract investor interest. SEC Form 4 filing
• Positive Sentiment: Zacks Research upgraded MYGN from “strong sell” to “hold,” removing a severe negative rating and potentially reducing selling pressure from some model-driven funds or algorithmic screens. Zacks.com
• Neutral Sentiment: Media coverage amplified the insider activity (TipRanks coverage), which can increase short-term trading volume and retail interest but does not change fundamentals by itself. TipRanks article
• Negative Sentiment: Management updated Q1 FY2026 guidance with revenue of $200.0M–$203.0M (consensus ~$203.5M) and left EPS guidance unspecified — revenue guidance is slightly below consensus and the missing EPS figure creates uncertainty ahead of the quarter, which can pressure the stock if investors focus on short-term top-line weakness. (Company guidance release)

Analyst Upgrades and Downgrades

MYGN has been the subject of a number of research analyst reports. UBS Group cut their target price on shares of Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday. Zacks Research raised Myriad Genetics from a “strong sell” rating to a “hold” rating in a research report on Thursday. TD Cowen restated a “hold” rating on shares of Myriad Genetics in a research note on Tuesday, November 4th. Piper Sandler cut their target price on shares of Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Finally, Wells Fargo & Company reduced their price target on shares of Myriad Genetics from $6.50 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday. Four investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.17.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.